Results 301 to 310 of about 1,121,449 (385)

Comparative study of adenosine 3′‐pyrophosphokinase domains of MuF polymorphic toxins

open access: yesFEBS Open Bio, EarlyView.
With the ultimate goal of understanding the association of toxin‐immunity modules to temperate phages, we characterized toxins from three prophages and examined cross‐protection from immunity proteins. The toxins exhibit adenosine 3′‐pyrophosphokinase activity and are toxic in Escherichia coli.
Eloïse M. Paulet   +6 more
wiley   +1 more source

Iron‐dependent lysosomal LDL oxidation induces the expression of scavenger receptor A in human THP‐1 monocytes

open access: yesFEBS Open Bio, EarlyView.
In human monocytic cells THP‐1, a limited uptake of native—not oxidized—LDL/VLDL induced expression of scavenger receptor A and cellular adhesion. Induction was inhibited by lysosomotropic (WR‐1065) and lipophilic (BHT) antioxidants and by siRNAs against ferritinophagy.
Martina Čierna   +4 more
wiley   +1 more source

Knockout of the mitoribosome rescue factors Ict1 or Mtrfr is viable in zebrafish but not mice: compensatory mechanisms underlying each factor's loss

open access: yesFEBS Open Bio, EarlyView.
Mitochondria contain two mitoribosome rescue factors, ICT1 and MTRFR (C12orf65). ICT1 also functions as a mitoribosomal protein in mice and humans, and its loss is lethal. Although Mtrfr knockout mice could not be generated, knockout zebrafish lines for ict1 and mtrfr were established.
Nobukazu Nameki   +11 more
wiley   +1 more source

Understanding and Overcoming Immunotherapy Resistance in Skin Cancer: Mechanisms and Strategies

open access: yesAging and Cancer, EarlyView.
This narrative review explores the mechanisms driving immunotherapy resistance in skin cancer, including tumor microenvironment factors, genetic mutations, and immune evasion strategies. It highlights potential strategies to overcome resistance, offering insights for improving therapeutic outcomes and guiding future research in personalized ...
Shreya Singh Beniwal   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy